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ABSTRACT  
Background: The prevalence of opioid use in pregnancy has increased sharply in recent years. 
Kentucky is one of the hardest hits states and has seen many babies born with withdrawal 
symptoms over the past decade. Recent years have seen an increase in efforts to decrease opioid 
use in both inpatient and outpatient settings. However, Kentucky continues to have high rates of 
opioid prescription. This study aims at looking at trends in Opioid Use Disorder (OUD) in 
pregnancy, Neonatal Opioid Withdrawal Syndrome(NOWS) and the use of opioids during 
delivery hospitalization at a Kentucky tertiary institution. 
Methods- Data on all deliveries between Jan 1st, 2013 and December 31st, 2017 were obtained 
from University of Kentucky Health Care.  Information on a total of 8,999 individual deliveries 
were included in the dataset. Using Cochrane-Armitage tests first and then logistic regression, 
the data were analyzed for trends in OUD, NOWS and the administration of opioids during 
delivery hospitalization. 
Results- An increase in prevalence of OUD in pregnancy (p<0.0001) and NOWS(p=0.007) was 
observed over the study period. No significant trend was observed in the use of opioids during 
vaginal delivery hospitalizations(p=0.07).  Among women who delivered vaginally, advancing 
maternal age was associated with slightly lower odds of inpatient opioid administration while 
tobacco use (OR=1.33, CI=1.04, 1.69), lower county income quartile (OR= 1.90, CI=1.09, 3.29) 
and unmarried status (OR=1.40, CI=1.16, 1.69) were significantly associated with higher odds of 
inpatient opioid administration. 
Conclusion- The findings of significant increases in NOWS over the years highlight the need for 
better family planning services targeted towards people of reproductive age with opioid use 
disorder. Better opioid stewardship is required to substantially reduce therapeutic opioid use.  
BACKGROUND INFORMATION 
Burden of the opioid epidemic 
Opioid Use Disorder (OUD) is described by the DSM-5 as a problematic pattern of 
opioid use leading to clinically significant impairment or distress.1 It is characterized by 
cravings, tolerance and a powerlessness to self-regulate use. 2  Despite its associated 
ramifications, prevalence of the disorder has continued to soar in recent years; with the United 
States recording a 3-fold increase in the rates of drug overdose deaths involving opioids between 
2000 and 2016.3,4 In the year 2017, over 65% of the 70,200 drug overdose deaths that occurred in 
the U.S. involved an opioid. It is estimated that approximately, 130 Americans die daily from 
opioid related overdoses. 5  In 2016 alone, the Commonwealth of Kentucky recorded 1404 
overdose deaths, up from 1248 reported in 2015.6 
 The disorder has steadily grown into one of epidemic proportions, presenting a major 
public health challenge. 7 
Opioid use is associated with not just mortality, but also significant rates of morbidity. 
Injection drug use puts individuals at a higher risk of cellulitis, bacteremia, osteomyelitis, 
endocarditis, abscesses, injection site ulcers, amongst other problem.8  A study in California 
found just under a third of the intravenous drug using population to have at some point 
experienced skin and soft tissue infections. 9  Another study conducted in England found a 36% 
prevalence of self-reported bacterial infection symptoms among People who inject drugs, 
PWIDs. 10  Yet another study, conducted in Baltimore found a 34.9% prevalence of any type of 
current wound among PWIDs.11 The sharing of needles predisposes PWID to HIV and Hepatitis 
C(HCV). The sharing of snorting straws and other drug equipment further increases the risk of 
HCV in this population and research from the Centers for Disease Control and Prevention (CDC) 
shows that the surge in the number of acute HCV infections observed in recent years has been 
driven by the opioid crisis.12  
The burden on the healthcare system has been tremendous. A study examining 394 drug-
related bacterial infection hospitalizations, over a 12- month period found 17 resultant deaths and 
a cumulative cost to the health care system of over 11 million USD.  Another study conducted 
between 2012 and 2015 found that compared to matched non-opioid using patients opioid 
abusing patients within the population incurred 14,810 USD more in health care utilization costs. 
8,13  It was estimated that in 2013 alone, prescription opioids misuse, abuse and dependence cost 
the United States around 78.5 billion USD and this amount does not include costs incurred from 
illegal opioid use.14  Research shows that the cost of the opioid epidemic to the United States 
economy between 2001 and 2017 was around 1 trillion USD.  This cost is expected to increase 
by 500 billion USD between 2018 and the year 2020.15  
Prior to 2010, most drug overdose deaths occurred in the 5th decade of life and were 
mostly cocaine related. However, prescription and synthetic opioids have slowly caught up, with 
synthetic opioids taking over as the leading culprits.16  Synthetic opioids have been responsible 
for overdose mortality mostly among young Non-Hispanic White males, living in urban areas 
and aged between 20 and 40 years.16  Prescription opioids on the other hand have been found to 
cause overdose mortality mostly among Non-Hispanic White females, living in rural areas and 
aged between 40 and 60 years. Overall, Non- Hispanic Whites appear to be more affected than 
Blacks and males more than females.16,17 In a retrospective study spanning a ten-year period, 
opioid overdosing was also found to be significantly associated with unmarried, unemployed 
status while adverse outcomes due to overdosing were correlated with use of psychotropic 
medications, comorbid physical and mental conditions as well as an increased level of 
prescription opioid usage.18 
The overall epidemic has mainly affected Non-Hispanic Whites of lower socio-economic 
status. Studies have found that patients admitted for IVDU related causes were more likely to be 
uninsured or beneficiaries of publicly funded insurance schemes such as Medicaid. 8,19  
Although, historically, heroin abuse was considered an urban inner-city problem, there has been 
a shift in trends with one study finding only 25% of users to be dwellers in large urban areas. The 
same study also observed that almost 90% of those initiating opioid use within the past ten years 
were Non- Hispanic Whites with a mean age of 22.9 years.16  This represents a deviation from 
older patterns in which opioid abuse began at a much younger age and was mostly a problem of 
minorities.16  
Opioid abuse in pregnancy 
Concomitant with the increase in OUD prevalence in the overall population, vulnerable 
subpopulations including the pregnant and parenting have also seen an increase in OUD 
prevalence. Evidence shows a greater than four-fold increase in prevalence of OUD at delivery 
hospitalization over the 5-year period between 1999 and 2014.19,20 OUD in pregnancy increases 
risk of pregnancy associated deaths and has been associated with adverse maternal outcomes.21  
Additionally, the incidence of neonatal opioid withdrawal syndrome(NOWS); a myriad of 
symptoms resulting from opioid withdrawal in babies born to opioid using mothers; is also 
reported to have increased by greater than 400% between 2004 and 2014. NOWS treatment is 
reported to have cost over half a billion USD in the year 2014 alone. Over 80% of that cost was 
covered by Medicaid, emphasizing the fact that the epidemic affects mostly people of lower 
socioeconomic status.3,19 
NOWS, sometimes referred to as Neonatal Abstinence Syndrome(NAS), is often attended 
by nervous and gastrointestinal system hyperactivity and often results in higher rates of 
complications such as seizures, feeding difficulties, meconium aspiration syndrome, etc., 
increased hospitalization costs and longer length of stay. 22-25 It has been recognized for a long 
time as developing from the termination, after delivery, of the maternofetal transfer of 
morphine.22-24 Although its management has improved over the years, factors that predict its 
occurrence in exposed babies are still not well established. 22,26 It is thought that volume of 
maternal opioid use, timing of last use and genetics play a role.22,26,27 
Some tools currently exist for screening newborns; however, the overall approach is not 
standardized.22,28,29 Given the fact that NOWS can occur as late as 7 days of life, after the 
neonate would usually have been discharged, it is important to identify more factors that could 
help predict its occurrence and severity. 30,31 Identifying these factors could potentially help 
clinicians with improving surveillance for and identification of NOWS.  
Infants born to women who use opioids have multiple layers of vulnerability. Opioids are 
able to cross the placenta and have been associated with an increased risk of adverse outcomes 
such as preterm delivery, some birth defects, poor fetal growth and still births. 32,33 In addition to 
these, mothers with OUD often have other factors that further contribute to maternal and 
infantile risk. These factors include intimate partner violence, concurrent use of other drugs and 
comorbid psychiatric disorders and in some cases inadequate health care.22,34-36 Although some 
researchers have questioned the role of confounding in the adverse pregnancy outcomes 
observed in OUD, the general consensus is that OUD in pregnancy is a serious condition with 
potentially severe outcomes.20,35,37-39  
 
From over-prescription to opioid crisis  
Excessive therapeutic use of opioids has primarily been blamed for the epidemic. The 
increasing prevalence of uncontrolled chronic pain, over the past three decades, coupled with 
cardiovascular and toxicity concerns surrounding non-opioid alternatives, led key players to seek 
out analgesic alternatives that were effective yet devoid of aforementioned concerns. Fueled by 
the assurance of minimal addiction potential provided by pharmaceutical companies, the practice 
of excessive and uncurtailed opioid prescription steadily became more prevalent. This effectively 
created an increasingly opioid dependent population and laid the foundation for the current crisis. 
40-43 
Although, beginning with prescription opioids, the current crisis has become more 
complicated over the years. The increasing awareness about the addiction potential coupled with 
the introduction of stricter regulatory measures and difficult to crush formulations resulted in a 
decreased availability of prescription opioids to a dependent population. The effect of this was an 
increasing propensity towards acquisition of opioids from alternative sources. These sources 
being illegal and unregulated, were more readily available and provided cheaper and often times 
more potent alternatives to prescription opioids.  Initially limited to mostly heroin, the spectrum 
of illicit drugs has now broadened to include illegally manufactured fentanyl and its analogs. 
42,44,45 
Even though the crisis has shifted to mostly illicitly obtained opioids, multiple studies 
have shown that most users have their first contact within opioids in a therapeutic context. 
Consequently, the need for minimal administration of opioids, while employing alternative 
methods of effective pain relief in settings of acute pain cannot be overemphasized. Recent 
studies have shown that there is an increasing awareness of this and although pain is often the 
primary reason for presentation in the ER, many ER providers are now cutting back on opioid 
administration.46-48 
Opioid use in obstetric pain management 
Pain is a commonly reported symptom within the obstetric setting, especially in the early 
post-partum period. Suboptimal pain control has the ability to increase risk of opioid use, result 
in post-partum depression, decrease a mother’s ability to care for her infant and to evolve into 
chronic pain. 37,49 Consequently, it is important to ensure that peri-partum pain is adequately 
controlled. Because of the risk of persistent opioid use after obstetric exposure in opioid naïve 
patients, American College of Obstetrics and Gynecology recommends a cautious, individualized 
approach to pain management that is stepwise, multimodal and maximizes other methods of pain 
management before resorting to opioids. 49 While complete avoidance of opioids is not the end 
goal, recent advocacy efforts are being targeted towards ensuring that opioids are only used 
when absolutely necessary. Currents recommendations encourage clinicians to consider non-
pharmacological methods of pain management such as sitz baths, cold, heat, etc., maximum 
acceptable doses of acetaminophen and NSAIDS and in appropriate situations, ultrasound guided 
nerve blocks and other analgesia techniques that could help avoid unnecessary opioid use. It is 
recommended that, in the event that opioids are required, they should be used in combination 
with other pain relief modalities, be limited, as much as possible to the short acting formulations 
and their duration of usage should be limited to the shortest possible effective duration.48-51  
Although studies have looked at trends in the use of opioids for acute pain management 
in the ER setting, not many have looked at such trends in the setting of peri-partum pain 
management. 47,52 One study did find that hospitals in the South are more likely to administer 
opioids during delivery hospitalization.53  Kentucky providers continue to prescribe high rates of 
opioids with an opioid prescription rate of 97 per 100 persons in the year 2015.54 Considering 
that a large study found 0.3% of women who had never been previously exposed to opioids 
becoming persistent users within one year of undergoing cesarean sections, it is important to 
examine how much opioids are being used for management of peri-partum pain. 51 This study 
aims to examine trends in maternal opioid use disorder, neonatal withdrawal syndrome and 
opioid administration during delivery hospitalization at a tertiary institution in Central Kentucky. 
METHODS 
 Data for the current study were obtained from the University of Kentucky Center for Clinical 
and Translational Science ( UK CCTS).  UK CCTS keeps data on all patients seen at UK 
Healthcare. De-identified maternal and infant data from all delivery hospitalizations between 
2013 and 2017 were requested. The initial dataset contained information on 8,999 unique 
deliveries. Information present within the dataset included hospitalization details such as length 
of stay, discharge disposition, payer, APR diagnostic groups, APR risk of mortality and APR 
severity of illness scores, diagnostic codes, medications administered and procedures performed.  
Demographic information including age, race, marital status, and county of residence were also 
present within the dataset. 
Using ICD-9 and ICD 10 CM codes (see appendix), data on OUD, diabetes mellitus, 
hypertension, renal disease, amphetamine abuse, cocaine abuse, tobacco use, cannabis use, HIV 
status, Hepatitis C status, mode of delivery, complications of delivery, thrombocytopenia, 
comorbid psychiatric conditions and Neonatal withdrawal symptoms were extracted from the 
data. Inferential procedures were performed for all predictors and outcomes of interests, and 
differences between the OUD and non-OUD groups were assessed using chi square analyses for 
categorical variables and t-tests for continuous variables. Results for this are presented in Table 
1. To examine temporal trends, Cochrane-Armitage test for trends were initially performed using 
year and the outcome of interest (OUD status, NOWS status and opioid use status). And then, to 
further explore the trends while controlling for possible confounding, a logistic regression model 
was fitted.  The logistic regression model for OUD in pregnancy was fitted using time (years), 
age (years), payer (Private, Bluecross /Blueshield, Medicaid, other), county income quartile 
(calculated using average county per capita personal income between 2015 and 2017 for every 
county represented in the data set. County per capita personal income data was obtained from 
The United States Bureau of Economic analyses, BEA. Available here: 
https://www.bea.gov/data/income-saving/personal-income-county-metro-and-other-areas), 
comorbidity count (calculated by assigning one point to each of the following risk factors: 
diabetes mellitus, renal disease, obesity and hypertension present in the individual record) and 
race (assigned as “White” versus “Other”).  Race was initially included as a variable with 
multiple levels but due to quasi complete separation of data points, it was then recoded as 
“White” versus “Non-White”, to allow for convergence of the model.  
For opioid administration during delivery hospitalization, only vaginal deliveries were 
considered. Cesarean sections are often associated with more severe pain than vaginal deliveries 
and the pain is often managed using co-analgesia55.  Consequently, they were left out of the 
analyses. Patients with bleeding disorders and renal disease, in whom NSAIDs may be 
contraindicated were excluded from the analyses because opioids may have been indicated in 
these patients.56 A total of 4562 records of women who had vaginal deliveries and met the 
inclusion criteria were included in the analyses. The adjustment variables were similar to those in 
the OUD model with the only differences being that, race was included as a 5-level variable 
(White, African American, Asian, Hispanic, other) and OUD (Yes versus No) and mode of 
delivery (operative vaginal i.e. forceps/vacuum vs vaginal) were added as additional adjustment 
variables. Opioid was defined as the presence of any opioid administered to a patient who 
delivered vaginally, during delivery hospitalization. 
Due to the fact that methadone and buprenorphine are indicated for treatment of OUD in 
pregnancy, their use in women with OUD was not considered in-hospital opioid administration 
for the purposes of this study34. 
 Information about NOWS was extracted, using all-encompassing ICD 9 CM and ICD 10 codes 
that cover all maternal drugs of addiction. These codes represented withdrawal symptoms in 
infant due to any maternal drug of addiction in use and was not specific to just opioids. A child 
was considered to have NOWS if those codes were present and the mother also had OUD. The 
logistic regression model was fitted with year of birth, maternal age, tobacco use, comorbid 
psychiatric conditions, marital status, county income quartile, substance use score (obtained by 
giving 1 point for each of the following substances in use: Cocaine, amphetamines and cannabis) 
and alcohol.  Because NOWS only occurs in babies exposed to opioids in-utero, the odds ratios 
were calculated using only babies born to mothers with OUD. Race was excluded from the 
model due to quasi complete separation of data points (resulting from the fact that majority of the 
mothers with OUD were White). 
All adjustment variables were selected a priori based on a review of literature. No variables were 
added on. 
RESULTS 
The overall prevalence of OUD in the population was 5.2% (n=465). Although significantly 
higher in the OUD than in the Non-OUD group, the overall prevalence of amphetamine abuse 
was negligible (0.06%). Prevalence of comorbid psychiatric disorders, cannabis use, cocaine use, 
tobacco use, was also significantly higher in the OUD group compared to the non-OUD group. 
More than 50% of the OUD population came from counties with per capita personal incomes in 
the lowest quartile, compared to only 23% of those in the non-OUD group (p value <.0001). HIV 
was rare within the population with only 0.1% having a diagnosis of HIV. Compared to the non-
OUD group, a significantly lower proportion of women with OUD were currently in a marriage 
relationship. (52.4% vs 15.3%).  Overall prevalence of any kind of withdrawal symptoms in the 
study population was 4%.  Neonatal opioid withdrawal symptoms specifically occurred in about 
3% of the overall population and half of the babies born to mothers with OUD. Table 1. 
The prevalence of opioid use and NAS significantly increased over the 5-year period. No 
significant trend was observed in in-hospital administration of opioids for peri-partum pain 
management. See Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
DESCRIPTIVE STATISTICS FOR THE STUDY POPULATION PRESENTED BY OUD 
STATUS. 
Maternal 
Characteristics 
Level Non-OUD 
n=8,534 
OUD 
n=476 
p-value 
Age - 28.62 (5.88) - 
(0.00,49.00) 
29.02 (4.82) - (17.00,47.00) 0.0594 
Amphetamines 
abuse 
Yes 2 (0.0%) 3 (0.6%) <.0001 
No 8521 (100.0%) 473 (99.4%) 
Cannabis use Yes 147 (1.7%) 28 (5.9%) 0001 
No 8376 (98.3%) 448 (94.1%) 
Cocaine Use Yes 56 (0.7%) 22 (4.6%) <.0001 
No 8467 (99.3%) 454 (95.4%) 
Comorbid 
Psychiatric 
disorder 
Yes 647 (7.6%) 154 (32.4%) 0001 
No 7876 (92.4%) 322 (67.6%) 
Comorbidity count  0.08 (0.30) - (0.00, 3.00) 0.05 (0.22) - (0.00, 2.00) 0.0132 
HIV Yes 10 (0.1%) 0 (0.0%) 0.4546 
No 8513 (99.9%) 476 (100.0%) 
Hepatitis C Yes 139 (1.6%) 217 (45.6%) <.0001 
No 8384 (98.4%) 259 (54.4%)  
Cesarean section Yes 3308 (38.8%) 229 (48.1%) <.0001 
No 5215 (61.2%) 247 (51.9%)  
Income Quartile Q1 1959 (23.0%) 276 (58.0%) <.0001 
Q2-Q3 6272 (73.6%) 191 (40.1%)  
Q4 279 (3.3%) 8 (1.7%)  
Missing 13 (0.2%) 1 (0.2%)  
Length of Stay*  2 (1.00, 338.00) 11 (1.00, 250.00) <.0001 
Marital Status Married 4442 (52.1%) 72 (15.1%) <.0001 
Unmarried 4081 (47.9%) 404 (84.9%) 
Neonatal 
Substance 
Withdrawal 
Yes 93 (1.1%) 238 (50.0%) <.0001 
No 8430 (98.9%) 238 (50.0%) 
Payer BlueCross/ 
Blueshield 
1145 (13.4%) 11 (2.3%) <.0001 
Medicaid 4971 (58.3%) 440 (92.4%) 
Private 625 (7.3%) 6 (1.3%) 
Other 1782 (20.9%) 19 (4.0%) 
Peri-partum opioid Yes 1070 (12.6%) 54 (11.3%) p-value=0.5568 
No 7453 (87.4%) 422 (88.7%) 
Race African 
American 
1050 (12.3%) 8 (1.7%) p-value=<.0001 
Asian 459 (5.4%) 0 (0.0%) 
Hispanic 94 (1.1%) 0 (0.0%) 
Other 166 (1.9%) 1 (0.2%) 
White 6754 (79.2%) 467 (98.1%) 
Tobacco Use Yes 917 (10.8%) 351 (73.7%) p-value=<.0001 
No 7606 (89.2%) 125 (26.3%) 
 Significance level is set at 0.05.  Please note that if cells counts are less than 5, the Chi-Square test p-value is unreliable. 
Percentages may not add up to 100 due to rounding 
*Median values were presented due to skewness of data, p value was estimated using Kruskal wallis test 
For continuous variables, the mean (standard error) - (minimum, maximum) is displayed in each cell  
 
 
 
Figure 1- Showing trends in OUD NAS and opioid administration during delivery 
hospitalization between 2013 and 2017. 
The odds of a pregnant woman presenting with OUD increased by 18% per year, on average. For 
every year increase in age, the odds of OUD increased by 8%, on average. Compared to non-
smokers, smokers had greater than 10 times the odds of having OUD.  Women from counties 
whose incomes fell in the lowest quartile had a 2.28 fold odds of OUD compared to those from 
the counties within the highest income quartile See table 2. 
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TABLE 2: LOGISTIC REGRESSION OUTCOMES FOR OUD (n=8,709) 
Maternal Characteristic Opioid Use Disorder 
Year, OR(CI) 
+1 1.20 (1.11, 1.30) 
Age, OR (CI) 
+1 1.09 (1.07, 1.11) 
Tobacco use, OR(CI) 
Yes vs No 10.30 (8.07, 13.15) 
Comorbid Psychiatric Condition, OR (CI) 
Yes vs No 2.48 (1.91, 3.23) 
Marital Status, OR (CI) 
Unmarried vs Married 2.75 (2.03, 3.72) 
Payer, OR (CI) 
Medicaid vs Private 5.91 (2.11, 16.56) 
Bluecross/ Blueshield vs Private 1.31 (0.40, 4.31) 
Other vs Private 1.48 (0.48, 4.58) 
County Income Quartile, OR (CI) 
Q1 vs Q4 2.67 (1.16, 6.10) 
Q2-3 vs Q4 1.04 (0.45, 2.37) 
Comorbidity Count, OR (CI) 
+1 0.38 (0.24, 0.61) 
Race, OR(CI) 
White vs non-White 7.93 (4.01, 15.70) 
 
Maternal age, smoking status, marital status, payer, county income and substance count did not 
significantly affect the occurrence of Neonatal withdrawal. See Table 3. 
 
 
 
 
 
 
 
 
 
 
TABLE 3: LOGISTIC REGRESSION OUTCOMES FOR NEONATAL OPIOID 
WITHDRAWAL SYNDROME (NOWS) 
 
 
Maternal Characteristic Neonatal withdrawal (n=238) 
Year, OR(CI) 
+1 0.94 (0.82,1.06) 
Race  
White vs other 0.48 (0.11.2.12) 
Age, OR (CI) 
+1 1.02 (0.98,1.06) 
Smoking, OR (CI) 
Yes vs No 1.09 (0.71,1.66) 
Marital status, (CI) 
Unmarried vs Married 1.67 (0.99, 2.8) 
County income quartile 
Q1 vs Q4 1.24 (0.27,5.67) 
Q2-3 vs Q4 1.54 (0.33, 7.09) 
Substance score 1.30 (0.76,2.23) 
 
 On average, the odds of receiving an opioid during a vaginal delivery hospitalization remained 
constant over the 5 year period. Increasing maternal age was significantly protective against 
inpatient opioid administration. Race, comorbidity count, mode of delivery and payer were not 
significantly associated with inpatient opioid administration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 4: SHOWING LOGISTIC REGRESSION RESULTS FOR OPIOID 
ADMINISTRATION DURING VAGINAL DELIVERY HOSPITALIZATION 
N=4562 
Maternal Characteristic Opioid administration  
Year, OR(CI)  
+1 1.03 (0.97, 1.08) 
Age, OR (CI)  
+1 0.97 (0.95, 0.98) 
Tobacco, OR(CI)  
Yes vs No 1.33 (1.04, 1.69) 
Comorbid Psychiatric condition, OR(CI)  
Yes vs No 1.30 (0.90, 1.87) 
Marital status, OR (CI)  
Unmarried vs Married 1.40 (1.16, 1.69) 
Payer, OR (CI)  
Medicaid vs Private 0.88 (0.62, 1.24) 
Bluecross/ Blueshield vs Private 0.96 (0.65, 1.41) 
Other vs Private 0.77 (0.52, 1.14) 
County income quartile, OR (CI)  
Q1 vs Q4 1.90 (1.09, 3.29) 
Q2-3 vs Q4 1.47 (0.86, 2.48) 
Comorbidity Count, OR (CI)  
+1 1.30 (0.90, 1.87) 
Mode of delivery, OR (CI)  
Operative vaginal vs vaginal 1.07 (0.36, 3.16) 
Laceration, OR (CI)  
Yes vs No 0.99 (0.83,1.19) 
Race, OR (CI)  
African American vs Asian 1.16 (0.75, 1.81) 
Hispanic vs Asian 1.32 (0.62, 2.84) 
White vs Asian 1.07 (0.72, 1.57) 
Other vs Asian 1.02 (0.52, 2.01) 
OUD, OR (CI)  
+1 0. 77 (0.52, 1.14) 
LOS 1.01 (1.00,1.01) 
	
 
 
 
 
DISCUSSION 
The current study looked at trends in and predictors of OUD in pregnancy, NOWS and opioid 
use during delivery hospitalization. Significant increases were observed in OUD and NOWS 
over time, but no significant changes were observed in overall inpatient opioid use.  This study 
builds on existing literature by examining the maternal sociodemographic characteristics 
associated with NOWS as well as those looking at factors associated with peri-partum opioid use 
within the inpatient setting. 
 The current findings confirm the previously documented association of White race, lower 
socioeconomic status, smoking, comorbid psychiatric conditions and increasing maternal age 
with OUD in pregnancy as well as the well documented increase in prevalence of OUD in 
pregnancy over the years. 2,19,20,57 
The observed increase in prevalence of NAS over the years highlights a need for family planning 
counselling and services to women of reproductive age in Kentucky, who have OUD. People 
with OUD are more likely to engage in risky sexual behavior and it is estimated that over 80% of 
pregnancies occurring in this population are unplanned.58,59 Guidelines issued by the Unites 
States Substance use and Mental Health Services Administration (SAMHSA), recommend that 
health care providers discuss family planning methods with women with OUD prior to 
discharge; as a means of reducing the occurrence of NAS. 56  The scaling up of family planning 
services at harm reduction centers could also help reduce the risk of unplanned pregnancies in 
women with OUD. In the face of a worsening opioid epidemic, action in this direction would be 
immensely beneficial.  
This study deviates from findings of higher odds of OUD in patients with cardiovascular 
comorbidities.35  Although individual comorbidities were not examined, comorbidity count; 
reflective of overall burden of cardiovascular disease was not significantly associated with OUD. 
Important to note is that obesity itself, as a stand-alone diagnosis, has been found to be 
associated with lower odds of OUD. 35,60 
None of the factors included in the model was significantly associated with NOWS. The 
occurrence of NOWS in infants of mothers with OUD has generally been considered difficult to 
predict. Factors such as genetics, maternal physiology and genetic polymorphisms which are 
thought to affect its expression are not routinely measured in the clinical setting.22,28,30,31 
Additionally, lack of information on timing of last use, quantity of use and poor-quality of 
information on gestational age was a limitation of this study. Although, the ability to predict 
which infants would get OUD would be ideal, in the absence of validated prediction tools, 
clinical astuteness is necessary. 31 Because the onset of NOWS can occur as late as greater than 
72 hours after delivery, a neonatal monitoring period of at least 5 days is recommended.30,31 A 
tool commonly used for clinical assessment is the modified Finnegan Score, however, this tool 
has been criticized as focusing on a number rather than a person.28,61 Effort need to be put into 
creating a valid, widely accepted tool that is simple to use and serves the purpose of improving 
clinical outcomes.31 
 The prevalence of opioid administration among patients who delivered vaginally was 
about 17.5%. This is higher than findings of a 12% prevalence in a nationwide study of opioid 
prescriptions following vaginal deliveries. 62 Despite the fact that there has been a push for less 
opioid use in the management of pain, the use of opioids did not significantly change with the 
passage of time. This suggests that there could be room for improving opioid stewardship. 48-50 
Because the perception of pain control has been shown to impact patient satisfaction, 
providers might feel dis-incentivized to try other analgesic methods. 63 However, this can be 
navigated by discussing patients’ expectations regarding pain; developing realistic pain 
management goals and developing an individualized plan along with the patient for managing 
perinatal pain. This should ideally be done during the antenatal period. 64 
Clinicians should employ a holistic approach to pain that could include psychological 
methods, if needed. Research has shown that pain management culture is more strongly 
correlated with patient satisfaction than actual perception of pain control. 63 Some centers have 
been able to cut back by as much as 40%; achieved by implementing multimodal pain therapy, 
individualized, goal directed therapeutic planning and more objective methods of measuring 
pain. 65 Similar methods could be employed at other tertiary institutions in an effort to bring 
about reductions in therapeutic opioid use. 
Concomitant with findings in a previous study, lacerations during vaginal deliveries were 
not significantly associated with opioid use.62  
OUD did not significantly impact the odds of in hospital opioid administration among the 
study population. Although, it might be tempting to think that in-hospital opioid use should be 
lower among people with OUD, it is important to note that opioids, although not encouraged, are 
not contraindicated in this population. 66-68  Because concerns have arisen about inadequate peri-
partum analgesia in women with OUD, clinical judgement is required when managing peri-
partum pain in this population.69  As with all cases, management should be individualized to 
ensure that pain management goals are achieved, while minimizing opioid use. 
Tobacco use was associated with higher odds of receiving an opioid. This is similar to 
findings from another study in which tobacco use was associated with a slight increase in odds of 
filling an opioid prescription within 5 days of vaginal delivery.62  Studies in post-operative 
settings have also found tobacco use to be associated with higher analgesic; particularly opioid 
requirement.70-72 It is thought that chronic use of nicotine results in tolerance to nicotine induced 
analgesia and that in such people, subsequent abstinence from nicotine e.g. in the post-partum 
period increases perception of pain.72 However, the mechanisms are not fully understood. More 
research is needed in this area72  
Lower socioeconomic status and unmarried status were positively associated with opioid 
administration. This is supported by findings from a study which showed that single women 
were more likely to perceive a higher pain intensity in the postoperative setting compared to their 
married counterparts. 73 Evidence has also shown socioeconomic status to be inversely related to 
perceived pain intensity. 74 The perception of pain is complex and multi-faceted and thought to 
be affected by psychological, social and environmental factors surrounding the perceiver. 75 
These factors could by extension affect in-hospital opioid requirements. Further studies that 
explore this are required. In order to achieve a reduction in unnecessary opioid use, providers 
would need to address patients’ needs holistically, employing pharmacological and non-
pharmacological techniques to achieve adequate pain control. 
Limitations of the current study include the fact that it depended on a previously existing 
dataset. Problems that could arise from this include exposure or outcome misclassification due to 
wrong coding and inadequate documentation. However, if there was exposure misclassification, 
the resultant bias is most likely to have been non-differential. There is likely to be underreporting 
of NOWS, because physicians are thought to be reluctant to diagnose NAS in instances where 
there was no morphine requirement. 76 Taking this into consideration, it can be concluded that 
NAS estimates obtained from this study are at best modest. 
Another limitation of this study was the fact that there was no data on what specific 
opioids were in use, how long they were in use and in what quantities they were used among the 
women who had OUD. Further studies should include a breakdown of drug use and quantities 
used.  
The dataset did not contain any information on pain intensity and provider characteristics, 
consequently, these variables could not be adjusted for when analyzing in-hospital opioid 
administration. Although, absence of this information does not eliminate the validity of findings 
from this study, these factors should be taken into consideration in future studies. 
Although this study looked at inpatient opioid use, it did not examine, nor does it predict 
post discharge prescription of opioids. Further studies that examine these two issues as a 
continuum are required. Insight into what proportion of patients who receive an inpatient opioid 
prescription go on to receive an outpatient prescription could help inform provider practices. In 
the face of the worsening opioid epidemic, cautious, evidence based use of opioids is highly 
warranted. 
CONCLUSIONS  
The current study demonstrates an increase in prevalence of OUD in pregnancy and 
Neonatal Opioid Withdrawal Syndrome among Central Kentucky women between 2013 and 
2017. It also demonstrates a constant prevalence of opioid administration during vaginal delivery 
hospitalization over the same period.  It is the first study of its kind to examine inpatient opioid 
use in women delivering at a tertiary institution in Kentucky.  
Strengths of the current study include the fact that it used a large dataset and was 
consequently sufficiently powered to detect effects of the exposures examined. The racial 
distribution within this study is comparable to that within the state of Kentucky suggesting that 
the racial distribution of the study population was representative of that of Kentucky. 77  
Although opioid usage policies could differ by institutions, it is expected that results from this 
study would stimulate conversations about opioid usage within in-patient settings. It is also 
hoped that findings from this study would set the stage for quality improvement efforts; aimed 
particularly at reducing opioid use in the management of acute pain. 
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APPENDIX 
ICD codes for comorbid psychiatric disorders: 
 "648.41" "296.8" "F41.0" "F41.1" "F43.0" "F60.3" "O99.344" "F41.9" "295.9" "311" "295.9" 
"300.01" "309.81" 
ICD codes for HIV: 
'042' '043' '044' 'Z21' 'B20.0' 'B20.1' 'B20.2' 'B20.3' 'B20.4' 'B20.5' 'B20.6' 'B20.7' 'B20.8' 'B20.9' 
'B21.0' 'B21.1' 'B21.2' 'B21.3' 'B21.7' 'B21.8' 'B21.9' 'B23.0' 'B23.1' 'B23.2' 'B23.8' 'B24' 'B22.0' 
'B22.1' 'B22.2' 'B22.7' 'B21.0' 
ICD codes for hypertension: 
'401.0' '401.1' '401.9' '402.00' '402.01' '402.10' '402.11' '402.90' '402.91' '403.00' '403.01' '403.10' 
'403.11' '403.90' '403.91' '404.00' '404.01' '404.02' '404.03' '404.10' '404.11'  
 '404.12' '404.13' '404.90' '404.91' '404.92' '404.93' '405.01' '405.09' '405.11' '405.19' '405.91' 
'405.99' 'I10' 'I11.0' 'I11.9' 
ICD codes for Diabetes Mellitus: 
'250.00' '250.01' '250.02' '250.03' '250.1' '250.2' '250.3' '250.4' '250.5' '250.6' '250.7' '250.8' '250.9' 
'E11.9' 'E13' 'E10' 'Z79.84' 'Z79.4' 
ICD codes for Renal Disease: 
'N18.1' 'N18.2' 'N18.3' 'N18.4' 'N18.5' 'N18.6' 'N18.9' '585.9' '585.6' '585.1' '585.2' '585.3' 
'585.4' '585.5' '583.81' '403.9' '586' '583.89' 
ICD codes for tobacco use: 
'F17.210' 'O99.334' 'F17.200' 'O99.333' '649.01' 
ICD codes for Obese: 
 '278.00' 'Z68.30' 'Z68.31'  'Z68.32' 'Z68.33' 'Z68.34' 'Z68.35' 'Z68.36' '278.01' '278.03' '793.91' 
'649.11' 'V85.30' 'Z68.37' 'Z68.38' ' Z68.39' 'Z68.41' ' Z68.42' ' Z68.43' ' Z68.44' ' Z68.45' 
'V85.31' 'V85.32' 'V85.33' 'V85.34' 'V85.35' 'V85.36' 'V85.37' ' V85.38' 'V85.39' 'V85.4' 'V85.41' 
' V85.42' '793.91' 'V85.43' 'V85.44' ' V85.45' 'V85.54' 'E66.0' 'E66.01' 'E66.2' 'E66.8' 'E66.9' 
'O99.214' '278' 
ICD codes for Cannabis: 
'F12.90' '305.2' '305.21' 'F12.10' 'F12.99' 'F12' 'F12.1' 'F12.2' 'F12.20' '304.30' '304.31' '304.32' 
ICD codes for Cocaine: 
'305.6' 'F14.10' '304.21' '305.61' 'F14.90' 'F14.129' '304.2' 'F14.20’ 
ICD codes for Alcohol: 
'F10.10' 'F10.20' '291.81' '291.0' '291.1' '291.2' '291.3' '291.4' '291.5' '291.8' '291.82' '291.89' 
'291.9' 'O99.314' '303.91' 'O99.310' '305' 
ICD codes for  
ICD codes for Bleeding disorders: 
'N17.0' '584.5' 'N17.1' 'N17.2' 'N17.8' 'N17.9' '584.6' '584.7' 
ICD codes for HCV: 
'V02.62' '070.54' '70.70' '070.44' '70.7' '70.54' '70.44' '70.71' '070.70' '070.71' 'B18.2' 'B18.20' 
'B19.20' 'B19.2' 'B17.1' 
ICD codes forCcesarean section: 
'O82' 'O82.0' 'O82.1' 'O82.2' 'O82.8' 'O82.9' '669.70' '669.7' '669.71' '649.8' 
ICD codes for 3rd degree laceration: 
'664.31' 'O70.3' 
ICD codes for 4th degree laceration: 
'664.21' 'O70.2' 'O70.20' 'O70.21' 
ICD codes for NAS: 
'P96.1' '779.5' 
ICD codes for Opioid use: 
'304.71' '304.72' 'E935.0' 'E850.0' 'E935.2' '305.50' '305.51' '305.52' '305.53' 'F11.20' 'F11.90' 
'305.5' '304' '304.00' '304.01' '304.02' '304.70' 'F11.10' 'F11' 'E850.2' '965.00' 'F11.23' '304.7' 
ICD codes for Operational Vaginal delivery: 
'669.51' '669.5' ' 669.50 ' 'O66.5' '660.71' 'P03.3' '763.3' 
ICD codes for Amphetamines: 
‘305.7’ ‘304.41’ ‘F15.10’ 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
